Intellia Therapeutics Inc (NTLA) Receives $38.00 Average Price Target from Analysts

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have been given an average rating of “Buy” by the thirteen ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $38.00.

NTLA has been the subject of a number of research reports. Barclays increased their target price on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 7th. JMP Securities initiated coverage on Intellia Therapeutics in a research note on Thursday, March 8th. They set an “outperform” rating for the company. BidaskClub raised Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 13th. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research note on Thursday, March 15th. Finally, Leerink Swann reissued an “outperform” rating on shares of Intellia Therapeutics in a research note on Wednesday, March 14th.

Shares of NTLA stock traded down $0.39 on Monday, reaching $25.26. The company had a trading volume of 23,885 shares, compared to its average volume of 1,049,812. Intellia Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.99. The stock has a market cap of $1.06 billion, a PE ratio of -13.75 and a beta of 3.21.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Tuesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.07. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. The business had revenue of $7.47 million during the quarter, compared to analysts’ expectations of $6.14 million. analysts anticipate that Intellia Therapeutics will post -2 EPS for the current year.

In other Intellia Therapeutics news, insider John M. Leonard sold 8,400 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jean Francois Formela sold 6,686 shares of the company’s stock in a transaction that occurred on Wednesday, May 16th. The stock was sold at an average price of $25.04, for a total value of $167,417.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,331 shares of company stock valued at $1,305,796. 3.20% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in NTLA. MetLife Investment Advisors LLC acquired a new position in Intellia Therapeutics during the 4th quarter worth approximately $146,000. Commonwealth Equity Services LLC acquired a new position in Intellia Therapeutics during the 1st quarter worth approximately $204,000. Cubist Systematic Strategies LLC acquired a new position in Intellia Therapeutics during the 1st quarter worth approximately $252,000. Slow Capital Inc. acquired a new position in Intellia Therapeutics during the 4th quarter worth approximately $294,000. Finally, D.A. Davidson & CO. acquired a new position in Intellia Therapeutics during the 4th quarter worth approximately $323,000. 60.74% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply